Clinical Trials
628 trialsSTARTRK-2
Hoffmann-La Roche
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
EVEREST-2
A2 Biotherapeutics Inc.
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
VERDI
Dana-Farber Cancer Institute
Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.
M.D. Anderson Cancer Center
EXCEED
Eli Lilly and Company
NEXUS-01
Eli Lilly and Company
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Terremoto Biosciences Inc.
FiREBOLT
Eli Lilly and Company
DESCENT-1
A2 Biotherapeutics Inc.
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Institutes of Health Clinical Center (CC)
TTBF
University of California, San Francisco
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
EMD Serono
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval
Agenus Inc.
The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.
New Phase Ltd.
A Study of PHST001 in Advanced Solid Tumors
Pheast Therapeutics
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
Peking University First Hospital
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
National Cancer Institute "Cancer Moonshot Biobank"
National Cancer Institute (NCI)
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
National Cancer Institute (NCI)
Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
AstraZeneca
The Vanguard Study: Testing a New Way to Screen for Cancer
National Cancer Institute (NCI)
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
BioNTech SE
A Study of DEG6498 in Participants With Solid Tumors
Degron Therapeutics Co.
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Compugen Ltd
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
National Institutes of Health Clinical Center (CC)
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Seagen Inc.
LONGEVITI
University of Alberta
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BeOne Medicines
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
Genentech, Inc.
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Cancer Research UK
MAGE-A4ᶜ¹º³²T for Multi-Tumor
USWM, LLC (dba US WorldMeds)
panSOHO
Bayer
PANEL
University Hospital, Rouen
FHAMe
University of Toronto
Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer
M.D. Anderson Cancer Center
Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing
Unity Health Toronto
iCaRe2
University of Nebraska
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Children's Oncology Group
CERTIS1
AstraZeneca
RAD301
Radiopharm Theranostics, Ltd
Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)
GE Healthcare